✦ LIBER ✦

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study

✍ Scribed by Javier De La Rubia; Mónica Roig; Ángela Ibáñez; Inmaculada García; José A. Vera; Carlos Aguilar; Raquel Del Campo; Nicolás González; Rafael Martínez; Luis Palomera; Isabel Picón; Juan N. Rodríguez; Miguel A. Sanz

Book ID: 114794825
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 64 KB
Volume: 85
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2010.01500.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The efficacy and safety of lenalidomide

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

✍ Meletios Dimopoulos; Adrian Alegre; Edward A. Stadtmauer; Hartmut Goldschmidt; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 1 views

Safety and efficacy of bortezomib-based

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA

✍ Fortunato Morabito; Massimo Gentile; Stefania Ciolli; Maria T. Petrucci; Sara Ga 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Patients with multiple myeloma requiring

Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases

✍ R. Torra; J. Blade; A. Cases; J. López-Pedret; E. Montserrat; C. Rozman; L. Reve 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

Multi-Dose Pharmacokinetic Study of Pler

Multi-Dose Pharmacokinetic Study of Plerixafor in a Morbidly Obese Patient with Multiple Myeloma and Dialysis-Dependent Renal Impairment

✍ J.M. Vozniak; L.E. Davis; E.A. Stadtmauer 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Phase II study of CLAD (cyclophosphamide

Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone)

✍ G. Hütter; H. Szélenyi; A. Schmittel; J. M. Siehl; E. Thiel; U. Keilholz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract The purpose of this study was to assess the efficacy and safety of pegylated liposomal doxorubicin in combination with cyclophosphamide and dexamethasone (CLAD). In this prospective open‐label phase II study, 60 patients with advanced multiple myeloma (MM) received three weekly cycles o

Intravenous infusion of pituitary adenyl

Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: A case study

✍ Min Li; Jerome L. Maderdrut; Juan J.L. Lertora; Vecihi Batuman 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 151 KB